Patient and tumor characteristics at baseline of anti-PD-1/PD-L1 therapy
| All patients n=114 (100%) | Disease control (BOR=CR/PR/SD) n=74 (100%) | Disease progression (BOR=PD) n=40 (100%) | |
| Patient characteristics | |||
| Gender | |||
| Male | 82 (72%) | 54 (73%) | 28 (70%) |
| Female | 32 (28%) | 20 (27%) | 12 (30%) |
| Age | |||
| <70 | 40 (35%) | 24 (32%) | 16 (40%) |
| ≥70 | 74 (65%) | 50 (68%) | 24 (60%) |
| Overall performance status (ECOG) | |||
| 0 | 64 (56%) | 47 (64%) | 17 (43%) |
| ≥1 | 49 (43%) | 26 (35%) | 23 (57) |
| Not available | 1 (1%) | 1 (1%) | 0 (0%) |
| Immunosuppression | |||
| No | 92 (81%) | 64 (86%) | 28 (70%) |
| Yes | 22 (19%) | 10 (14%) | 12 (30%) |
| LDH (blood) | |||
| Normal | 43 (38%) | 32 (43%) | 11 (28%) |
| Elevated | 67 (59%) | 39 (53%) | 28 (70%) |
| Not available | 4 (3%) | 3 (4%) | 1 (2%) |
| CRP (blood) | |||
| Normal | 30 (26%) | 21 (28%) | 9 (23%) |
| Elevated | 55 (48%) | 31 (42%) | 24 (60%) |
| Not available | 29 (26%) | 22 (30%) | 7 (16%) |
| NLR (blood) | |||
| ˂4 | 54 (47%) | 36 (49%) | 18 (45%) |
| ≥4 | 35 (31%) | 20 (27%) | 15 (38%) |
| Not available | 25 (22%) | 18 (24%) | 7 (17%) |
| Tumor characteristics | |||
| Localization of primary | |||
| Head and neck | 24 (21%) | 17 (23%) | 7 (17%) |
| Extremities | 44 (39%) | 27 (36%) | 17 (43%) |
| Trunk | 19 (17%) | 12 (16%) | 7 (17%) |
| Unknown primary | 15 (13%) | 9 (12%) | 6 (15%) |
| Metastatic stage (AJCC) | |||
| M0 | 17 (15%) | 11 (15%) | 6 (15%) |
| M1a | 36 (32%) | 23 (31%) | 13 (32%) |
| M1b/M1c | 61 (53%) | 40 (54%) | 21 (53%) |
| Organs involved | |||
| 1 | 51 (45%) | 38 (51%) | 13 (32%) |
| >1 | 63 (55%) | 36 (49%) | 27 (68%) |
| MCPyV status (tumor) | |||
| Negative | 10 (9%) | 6 (8%) | 4 (10%) |
| Positive | 32 (28%) | 20 (27%) | 12 (30%) |
| Not available | 72 (63%) | 48 (65%) | 24 (60%) |
| PD-L1 (tumor) | |||
| Negative | 17 (15%) | 11 (15%) | 6 (15%) |
| Positive | 21 (18%) | 12 (16%) | 9 (23%) |
| Not available | 76 (67%) | 51 (69%) | 25 (62%) |
| Therapeutic interventions | |||
| Previous radiotherapy | |||
| No | 55 (48%) | 35 (47%) | 20 (50%) |
| Yes | 59 (52%) | 39 (53%) | 20 (50%) |
| Previous chemotherapy | |||
| No | 83 (73%) | 53 (72%) | 30 (75%) |
| Yes | 31 (27%) | 21 (28%) | 10 (25%) |
| PD-1/PD-L1 inhibitor therapy | |||
| Avelumab | 57 (50%) | 33 (45%) | 24 (60%) |
| Nivolumab | 13 (11%) | 10 (13%) | 3 (8%) |
| Pembrolizumab | 44 (39%) | 31 (42%) | 13 (32%) |
AJCC, American Joint Committee on Cancer; BOR, best overall response; CRP, C reactive protein; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MCPyV, Merkel cell polyomavirus; NLR, neutrophil to lymphocyte ratio.